Intellia Therapeutics, Inc. (NASDAQ:NTLA), ended the day at $12.62, a rise of 1.2 per cent and a share price that brought its market capitalization to $625.12 million. The company’s EPS for trailing 12 months is $-2.11 and its annual dividend yield is 0% with a payout ratio of 0%. It is estimated to be posting an EPS of $-0.45 for the current quarter. The Beta number showed the stock is subject to risk 76% more than the market as a whole. In the trailing twelve months, its return on assets (ROA) is -28.9% while ROE for the same period is -36.6%.
Intellia Therapeutics, Inc. (NASDAQ: NTLA) that works focusing around developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application submitted by its collaborator, Novartis, for a CRISPR/Cas9-based engineered cell therapy for the treatment of sickle cell disease (SCD).
In the 1/2 phase of this clinical trial, the leading genome editing company will begin investigating OTQ923 in adult patients with severe complications of SCD. OTQ923 is a SCD treatment based on genome editing of hematopoietic stem cells (HSCs), using CRISPR/Cas9 RNA guides identified through Intellia’s cell therapy research collaboration with Novartis. This therapeutic approach results in highly targeted editing of the HSC’s DNA to induce fetal hemoglobin (HbF) expression. The edited cells are returned to the patient, where the expression of HbF is expected to reduce the deleterious effects of sickle hemoglobin (HbS). Novartis’ IND application triggered a milestone payment to Intellia, and the company is eligible to receive additional downstream success-based milestones and royalties.
The outstanding share count is 50.13 million shares but the size of available float is 40.74 million shares. The stock’s current price is lagging SMA-200 by -12.35% which is also -2.44% down from SMA-50. Reducing that period to a shorter term, we see the price is trailing 5.84% to the SMA-20. Volatility for the week was 6.81%, which was 1.03% in the previous month. The company closed the session with a trading volume of 498752 shares, below from its average daily trading volume of 760.2 million.
It has been generating revenue of $43.1 million while net income posted by the company in last 12 months was -$99.50 million. When looking at performance, we see the stock demonstrating a weekly performance of 11.94% while keeping a monthly performance of -9.44%. Quarterly performance saw a drop of -18.01% and continued the negative trend with a yearly performance of -27.71% while showing YTD performance of -15% which was 15.36% for last six months.
The 52-week range for the stock was 9.18 – 19.00 that put its current price at a premium of 37.47% to the 52-week low price whereas it is trading at a discount of -33.58% to the 52-week high price.